#USA #Inc. #healthcare #Alameda #Penumbra #thrombectomy

Penumbra, Inc.: Financial Insights for Fourth Quarter and Full Year 2025

On January 15, 2026, Penumbra, Inc. (NYSE: PEN), recognized as the premier thrombectomy company globally, disclosed its preliminary financial results for the fourth quarter and the overall performance for the year 2025. The report reflects both commendable growth and profitability amidst a challenging healthcare environment.

Financial Performance Overview

Fourth Quarter Highlights

In the fourth quarter of 2025, Penumbra's revenue ranged between $383.0 million and $384.8 million, translating to an impressive year-on-year growth of approximately 21.4% to 22.0% compared to the corresponding quarter in 2024. Notably, when excluding revenues impacted by operations in China, the growth rate soared even higher, landing between 23.2% and 23.8%.

Full Year Financials

For the entire fiscal year 2025, Penumbra recorded revenues between $1,401.3 million and $1,403.1 million, marking a substantial increase of approximately 17.3% to 17.5% from the previous year. Again, when China’s regional impacts are excluded, the company’s revenue growth was favorably enhanced to around 24.7% to 24.9%.

Profitability Metrics

The company also showcased robust gross margins, reporting 67.9% to 68.1% for Q4 2025 and a stable 67.1% average gross margin for the full year. This reflects Penumbra's efficiency in managing production costs relative to its sales, indicating strong operational performance.

Operational Income

In terms of operational income, the fourth quarter revealed earnings between $56.9 million and $60.4 million, with an operating margin of 14.8% to 15.7%. For the full year, the operational income was reported between $186.9 million and $190.4 million, equating to an operating margin of 13.3% to 13.6%.

Company Overview

Penumbra, Inc. is committed to advancing medical technology, especially within thrombectomy, which is pivotal in treating conditions like ischemic stroke, and acute limb ischemia, among others. Their innovative portfolio includes solutions such as computer-assisted vacuum thrombectomy (CAVT), aimed at efficiently and safely removing blood clots. This technology has proven vital, as it aids healthcare professionals in more than 100 countries, fostering improved patient outcomes and significant enhancements to quality of life.

Penumbra's position in the healthcare industry and continuous efforts to innovate emphasize its dedication to excellence. The company continues to thrive by aligning its strategies with patient needs, ensuring that advancements in thrombectomy contribute positively to global health.

For further information, you can visit their official website at penumbrainc.com and follow their updates on platforms like Instagram, LinkedIn, and X to gain insights into their latest innovations and developments in healthcare.

Conclusion

Overall, Penumbra, Inc. has shown exceptional performance throughout 2025, signaling strong prospects for future growth and continued leadership in thrombectomy solutions. As they navigate the evolving healthcare landscape, their financial resilience indicates a robust capability to meet industry demands while prioritizing patient safety and technological advancement.